p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2

Apoptosis

Volumn 11, Issue 3, 2006, Pages 413-425

  Bu, S Z ^a   Huang, Q ^b   Jiang, Y M ^a   Min, H B ^c   Hou, Y ^a   Guo, Z Y ^b   Wei, J F ^d   Wang, J W ^a   Ni, X ^a   Zheng, S S ^d  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c 455 Hospital   (China)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

2 Methoxyestradiol; Apoptosis; Bcl 2; Ovarian cancer; p38

Indexed keywords

2 METHOXYESTRADIOL; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ESTRADIOL; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MUTANT PROTEIN; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN OVCAR 3; CONTROLLED STUDY; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG MECHANISM; ENZYME INHIBITION; ESTROGEN METABOLISM; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUOROMETRY; HUMAN; HUMAN CELL; MUTATION; NORMAL HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DNA FRAGMENTATION; EPITHELIAL CELLS; ESTRADIOL; FEMALE; HUMANS; OVARIAN NEOPLASMS; OVARY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUBULIN MODULATORS;

EID: 33646390930     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-4064-z     Document Type: Article

References (60)

1. Zhu BT, Conney AH. Is 2-Methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998; 58: 2269-2277.
2. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-Methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 2001; 127: 405-410.
3. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 2002; 62: 3691-3697.
4. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999; 86: 1013-1018.
5. Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case-control study. Survey of Women's Health Study Group. Int J Cancer 1995; 62: 678-684.
6. Writing Group for the Women's Health Initiative Investigators. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-1712.
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
8. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.
9. Mahavni V, Sood AK. Hormone replacement therapy and cancer risk. Curr Opin Oncol 2001; 13: 384-389.
10. Weiss NS, Rossing MA. Oestrogen-replacement therapy and risk of ovarian cancer. Lancet 2001; 358: 438.
11. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 2001; 142: 2351-2360.
12. Wang TT, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995; 55: 2487-2489.
13. Perillo B, Sasso A, Abbondanza C, Palumbo G. 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing Bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 2000; 20: 2890-2891.
14. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang HG. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 1994; 91: 9238-9242.
15. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92: 4507-4511.
16. Attalla H, Westberg JA, Andersson LC, Adlercreutz H, Makela TP. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: Uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun 1998; 247: 616-619.
17. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol Rev 1999; 79: 143-180.
18. Cobb MH. MAP kinase pathways. Prog Biophys Mol Boil 1999; 71: 479-500.
19. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
20. Karin M. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann NY Acad Sci 1998; 851: 139-146.
21. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-874.
22. Kyriakis JM. Making the connection: Coupling of stress-activated ERK/MAPK (extracellular-signal-regulated kinase/mitogen-activated protein kinase) core signalling modules to extracellular stimuli and biological responses. Biochem Soc Symp 1999; 64: 29-48.
23. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000; 275: 38953-38956.
24. Wilkinson MG, Millar JB. SAPKs and transcription factors do the nucleocytoplasmic tango. Genes Dev 1998; 12: 1391-1397.
25. Torcia M, De Chiara G, Nencioni L, Ammendola S, Labardi D, Lucibello M, Rosini P, Marlier LN, Bonini P, Dello Sbarba P, Palamara AT, Zambrano N, Russo T, Garaci E, Cozzolino F. Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release. J Biol Chem 2001; 276: 39027-39036.
26. Tsao SW, Mok SC, Fey EG, Fletcher JA, Wan TS, Chew EC, Muto MG, Knapp RC, Berkowitz RS. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995; 218: 499-507.
27. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998; 25: 281-304.
28. Rago R, Mitchen J, Wilding G. DNA florometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distill water. Anal Biochem 1990; 191: 31-34.
29. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 1996; 16: 1247-1255.
30. Brinster RL, Allen JM, Behringer RR, Gelinas RE, Palmiter RD. Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci USA 1988; 85: 836-840.
31. Rakesh KS, Mi Q-S, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999; 96: 3775-3780.
32. Chien CH, Wang FF, Hamilton TC. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol 1994; 99: 11-19.
33. Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 1992; 75: 1497-1502.
34. Langdon SP, Hirst GL, Miller EP, Hawkins RA, Tesdale AL, Smyth JF, Miller WR. The regulation of growth and protein expression by estrogen in vitro: A study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 1994; 50: 131-135.
35. Wimalasena J, Meehan D, Cavallo C. Human epithelial ovarian cancer cell steroid secretion and its control by gonadotropins. Gynecol Oncol 1991; 41: 56-63.
36. Steinkampf MP, Mendelson CR, Simpson ER. Regulation by follicle-stimulating hormone of the synthesis of aromatase cytochrome P-450 in human granulosa cells. Mol Endocrinol 1987; 1: 465-471.
37. Mendelson CR, Cleland WH, Smith ME, Simpson ER. Regulation of aromatase activity of stromal cells derived from human adipose tissue. Endocrinology 1982; 111: 1077-1114.
38. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331: 771-776.
39. Viqar S, Gregory U, Mok SC, Yiu GK, Ho S-M. Expression of Gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001; 61: 6768-6776.
40. Bu S, Blaukat A, Fu X, Heldin NE, Landstrom M. Mechanisms for 2-Methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 2002; 531: 141-151.
41. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-Methoxyestradiol and taxol. Cancer Res 1997; 57: 81-86.
42. Kataoka M, Schumacher G, Cristiano RJ, Atkinson EN, Roth JA, Mukhopadhyay T. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res 1998; 58: 4761-4765.
43. Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. Potent antitumor activity of 2-Methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 1999; 5: 493-499.
44. Shimada K, Nakamura M, Ishida E, Kishi M, Konishi N. Roles of p38- and c-Jun NH2-terminal kinase-mediated pathways in 2-Methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 2003; 24: 1067-1075.
45. Seegers JC, Lottering ML, Grobler CJ, van Papendorp DH, Habbersett RC, Shou Y, Lehnert BE. The mammalian metabolite, 2-Methoxyestradiol, affects p53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol 1997; 62: 253-267.
46. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-395.
47. Rosini P, De Chiara G, Lucibello M, Garaci E, Cozzolino F, Torcia M. NGF withdrawal induces apoptosis in CESS B cell line through p38 MAPK activation and Bcl-2 phosphorylation. Biochem Biophys Res Commun 2000; 278: 753-759.
48. Gupta S, Campbell D, Derijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995; 267: 389-393.
49. Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997; 57: 2388-2393.
50. Shan R, Price JO, Gaarde WA, Monia BP, Krantz SB, Zhao ZJ. Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCD-57 cells induced by withdrawal or addition of erythropoietin. Blood 1999; 94: 4067-4076.
51. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994; 91: 3964-3968.
52. Hsu SC, Gavrilin MA, Tsai MH, Han J, Lai MZ. p38 mitogen-activated protein kinase is involved in Fas ligand expression. J Biol Chem 1999; 274: 25769-25776.
53. Mukhopadhyay T, Roth JA. Superinduction of wild-type p53 protein after 2-Methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene 1998; 17: 241-246.
54. Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J 1997; 16: 968-977.
55. Haldar S, Chintapalli J, Croce CM. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-1255.
56. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin 2000; 50: 7-33.
57. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001; 285:1460-1465.
58. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 1996; 63: 533-534.
59. Kaufman DW, Kelly JP, Welch WR, Rosenberg L, Stolley PD, Warshauer ME, Lewis J, Woodruff J, Shapiro S. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989; 130: 1142-1151.
60. Hempling RE, Wong C, Piver MS, Natarajan N, Mettlin CJ. Hormone replacement therapy as a risk factor epithelial ovarian cancer: Results of a case control study. Obstet Gynecol 1997; 89: 1012-1016.